Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20391832 | 0.82 | RECQL (0.44) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL3298262 | 0.82 | PGK1 (0.50) | PGK1PGK2ADORA2AALDH1A1 | |
| SCHEMBL954513 | 0.80 | CCR1 (0.52) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL102150 | 0.78 | CCR1 (0.50) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL14577729 | 0.76 | CCR1 (0.48) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL21649830 | 0.76 | PGK1 (0.42) | NOS3NOS2PGK1PGK2ALDH1A1 | |
| SCHEMBL23343749 | 0.76 | ADORA2A (0.37) | NOS2PGK1PGK2ADORA2ANPSR1 | |
| SCHEMBL22299565 | 0.74 | CCR1 (0.46) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL24375835 | 0.74 | CCR1 (0.46) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL20738713 | 0.74 | CCR1 (0.46) | CCR1CCR8RECQLHTTNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076967-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-12478624-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| WO-2023130054-A2 | HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2023-07-06 | — | — | WO | disclosed |
| US-20230064948-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| WO-2022268209-A1 | DERIVATIVE HAVING PYRIMIDINE-FUSED CYCLIC STRUCTURE, AND USE THEREOF | 四川汇宇制药股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-11312705-B2 | Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-04-26 | — | — | US | disclosed |
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | NIKANG THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| WO-2021222404-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN BIOTECH, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021155320-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-11078193-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2021-08-03 | — | — | US | disclosed |
| US-7968587-B2 | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| EP-2094658-A2 | TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008063867-A2 | TETRAHYDROCYCLOPENTA[B] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063867-A2 | TETRAHYDROCYCLOPENTA[B] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008051405-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | ADORA2A, ADORA1, ADORA3 | CCR1 678/4885CCR8 1229/4885RECQL 1625/4885 |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | CCR1 3313/4885CCR8 2654/4885RECQL 4486/4885 |
| US-20260076967-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, XDH, SLC10A1 | CCR1 26/4885CCR8 530/4885RECQL 1392/4885 |
| US-11312705-B2 | Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof | ADORA2A, ADORA1, ADORA3 | CCR1 2042/4885CCR8 903/4885RECQL 1089/4885 |
| US-20230064948-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | SLC10A1, SLC6A6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CCR1 1114/4885CCR8 2009/4885RECQL 2209/4885 |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, MUSK | CCR1 771/4885CCR8 1467/4885RECQL 4562/4885 |
| US-11078193-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | RB1, SRR, RRP12 | CCR1 2328/4885CCR8 1926/4885RECQL 102/4885 |
| US-12478624-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, SLC6A6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CCR1 1114/4885CCR8 2009/4885RECQL 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.